ESR2 and ovarian carcinoma: Patients with ovarian cancers not expressing cytoplasmic ERβ had a median survival of 1628 days, whereas in the cohort with cytoplasmic ERβ expressing tumors, survival was still more than 50% at the longest time point (hazard ratio (HR) 1.842; 95% CI 1.040–3.264) (Fig. 3).